Thrombopoietin receptor MPL (TPO-R) is a proto-oncogene whose ligand (TPO) has been recently promoted as a marker for ovarian cancer and with existing agonists [26]: found higher levels associated with more advanced cases and levels of serum thrombopoietin decreased after primary treatment. Here, TPO is linked to ovarian cancer.